VX-561: Clinical Trials

4 trials of VX-561, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 recruiting. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Completed 2, Recruiting 2
Phase 21Completed 1

Follow VX-561: new trials by email Literature Review of VX-561 trials Research Report on VX-561

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants
VX-272, Placebo, Tezacaftor - Cystic Fibrosis
Phase 1RecruitingVertex Pharmaceuticals Incorporated1602026-02-252026-09-23
Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis
VX-581, Placebo, D-IVA - Cystic Fibrosis
Phase 1RecruitingVertex Pharmaceuticals Incorporated1522025-12-092026-10-19
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
VX-828, Placebo, Itraconazole - Cystic Fibrosis
Phase 1CompletedVertex Pharmaceuticals Incorporated1652023-12-122026-08-10
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
IVA, TEZ/IVA, VX-445 - Cystic Fibrosis
Phase 1 / Phase 2CompletedVertex Pharmaceuticals Incorporated2252017-01-232022-01-18

Conditions studied

Cystic Fibrosis (4)

Sponsors

Vertex Pharmaceuticals Incorporated (4)

Countries

United States (4)  ·  Australia (1)  ·  Belgium (1)  ·  Netherlands (1)

Results publications

PMID 30334692, PMID 33331662, PMID 37983082

NIH funding

2017 (1)